Phosphagenics has reported successful completion of a phase 1 clinical study of its patented oxycodone transdermal matrix patch system. The results of the trial established that after a
Jim Manzi, chairman of the board, said, “Marc’s strong leadership at Thermo Fisher over the past eight years and his achievements both here and in other companies make
Lexicon Pharmaceuticals (Lexicon) has initiated a phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug
Wyeth Pharmaceuticals has reported the findings from a placebo-controlled phase 3 study of bazedoxifene 20mg extended to five years, which indicated a significant reduction versus placebo in new
The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. Monovalent Vaccine is an inactivated influenza virus
Addex Pharmaceuticals’ (Addex) ADX10059 has demonstrated significant potential in a non-human primate model of Parkinson’s disease levodopa induced dyskinesia (PD-LID). ADX10059 is an allosteric inhibitor – a negative
OctoPlus has signed a pharmaceutical development and manufacturing contract with Axentis Pharma. The undisclosed contract value contributes to OctoPlus’ annual revenues, for which the company reiterates its guidance
Kenta Biotech (Kenta) has provided positive phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia
The FDA has accepted for filing Mylan’s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20mg/mL), a generic version of Teva’s Copaxone. The product is indicated for
The Chinese State Food and Drug Administration (SFDA) has approved Abbott’s XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) The company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.